VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN

Abstract. We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Cherdantsev, M. Kostinov, А. Kuselman, Y. Dagil, A. A. Savis’ko
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	influenza pregnancy vaccination Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c76253e92ee940d1ae843281e0d125cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c76253e92ee940d1ae843281e0d125cd
record_format	dspace
spelling	oai:doaj.org-article:c76253e92ee940d1ae843281e0d125cd2021-11-18T08:03:42ZVACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN1563-06252313-741X10.15789/1563-0625-2012-6-527-532https://doaj.org/article/c76253e92ee940d1ae843281e0d125cd2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/612https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippol plus” vaccine. The second group consisted of thirty-seven pregnant women immunized by trivalent “Grippol plus” vaccine. Thirty-one pregnant women (III group) received placebo treatment. Non-pregnant women (IV group) were injected with “MonoGrippol plus”. We did not find any differences in clinical features of vacccine-challenged time period in pregnant women from groups I-III. Notably, sufficient numbers of women were found to be seroprotected 1 month post-vaccination (I group, 80.0% ; II group, 75.7% ; IVgroup, 80.6% ) with high levels seroconversion (I group, 46.6%; II group, 51.4%; IV group, 53.3%). Within 9-10 months after vaccination, a decreased seroprotection was revealed in II group of pregnant women. More stable specific immunity levels were detected for the groups immunized with univalent vaccine.Hence, the local subunit adjuvant “MonoGrippol plus” and “Grippol plus” vaccines were shown to exibit a high immune resistance efficiency profile and clinical safety, when used in pregnant women, thus presuming an extended application field for these biological drugs in public health service. State of pregnancy seems not to be a limiting condition for induction of specific immune resistance.A. CherdantsevM. KostinovА. KuselmanY. DagilA. A. Savis’koSPb RAACIarticleinfluenzapregnancyvaccinationImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 14, Iss 6, Pp 527-532 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	influenza pregnancy vaccination Immunologic diseases. Allergy RC581-607
spellingShingle	influenza pregnancy vaccination Immunologic diseases. Allergy RC581-607 A. Cherdantsev M. Kostinov А. Kuselman Y. Dagil A. A. Savis’ko VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
description	Abstract. We studied immune resistance efficiency of vaccination against influenza A/California/7/2009(H1N1)v in women at second trimester of physiological pregnancy in a blind, placebocontrolled study. The first group included thirty pregnant women who were injected by univalent subunit “MonoGrippol plus” vaccine. The second group consisted of thirty-seven pregnant women immunized by trivalent “Grippol plus” vaccine. Thirty-one pregnant women (III group) received placebo treatment. Non-pregnant women (IV group) were injected with “MonoGrippol plus”. We did not find any differences in clinical features of vacccine-challenged time period in pregnant women from groups I-III. Notably, sufficient numbers of women were found to be seroprotected 1 month post-vaccination (I group, 80.0% ; II group, 75.7% ; IVgroup, 80.6% ) with high levels seroconversion (I group, 46.6%; II group, 51.4%; IV group, 53.3%). Within 9-10 months after vaccination, a decreased seroprotection was revealed in II group of pregnant women. More stable specific immunity levels were detected for the groups immunized with univalent vaccine.Hence, the local subunit adjuvant “MonoGrippol plus” and “Grippol plus” vaccines were shown to exibit a high immune resistance efficiency profile and clinical safety, when used in pregnant women, thus presuming an extended application field for these biological drugs in public health service. State of pregnancy seems not to be a limiting condition for induction of specific immune resistance.
format	article
author	A. Cherdantsev M. Kostinov А. Kuselman Y. Dagil A. A. Savis’ko
author_facet	A. Cherdantsev M. Kostinov А. Kuselman Y. Dagil A. A. Savis’ko
author_sort	A. Cherdantsev
title	VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
title_short	VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
title_full	VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
title_fullStr	VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
title_full_unstemmed	VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN
title_sort	vaccine-challenged immune resistance toward virus a/california/7/2009(h1n1)v in immunized pregnant women
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/c76253e92ee940d1ae843281e0d125cd
work_keys_str_mv	AT acherdantsev vaccinechallengedimmuneresistancetowardvirusacalifornia72009h1n1vinimmunizedpregnantwomen AT mkostinov vaccinechallengedimmuneresistancetowardvirusacalifornia72009h1n1vinimmunizedpregnantwomen AT akuselman vaccinechallengedimmuneresistancetowardvirusacalifornia72009h1n1vinimmunizedpregnantwomen AT ydagil vaccinechallengedimmuneresistancetowardvirusacalifornia72009h1n1vinimmunizedpregnantwomen AT aasavisko vaccinechallengedimmuneresistancetowardvirusacalifornia72009h1n1vinimmunizedpregnantwomen
_version_	1718422507795513344

VACCINE-CHALLENGED IMMUNE RESISTANCE TOWARD VIRUS A/CALIFORNIA/7/2009(H1N1)v IN IMMUNIZED PREGNANT WOMEN

Ejemplares similares